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Abstract:  
 
Background & Aims: Adenoma detection rate (ADR) is an important quality assurance 
measure for colonoscopy. Some studies suggest that narrow band imaging (NBI) may be 
more effective at detection of adenomas than white-light endoscopy (WLE) when bowel 
preparation is optimal. We conducted a meta-analysis of data from individual patients in 
randomized controlled trials that compared the efficacy of NBI to WLE in detection of 
adenomas. 
 
Methods: We searched MEDLINE, EMBASE, and Cochrane library databases, through April 
2017, for randomized controlled trials that assessed detection of colon polyps by high-
definition WLE vs NBI and from which data on individual patients was available. The primary 
outcome measure was ADR adjusted for bowel preparation quality. Multilevel regression 
models were used with patients nested within trials, and trial included as a random effect. 
 
Results: We collected data from 11 trials, comprising 4491 patients and 6636 polyps 
detected. Adenomas were detected in 952/2251 (42.3%) participants examined by WLE vs 
1011/2239 (45.2%) participants examined by NBI (unadjusted odds ratio [OR] for detection 
of adenoma by WLE vs NBI, 1.14; 95% CI, 1.01–1.29; P=.04). NBI outperformed WLE only 
when bowel preparation was best: adequate preparation OR, 1.07 (95% CI, 0.92–1.24; P=.38) 
vs best preparation OR, 1.30 (95% CI, 1.04–1.62; P=.02). Second-generation bright NBI had a 
better ADR than WLE (second-generation NBI OR, 1.28; 95% CI, 1.05–1.56; P=.02), whereas 
first-generation NBI did not. NBI detected more non-adenomatous polyps than WLE (OR, 
1.24; 95% CI, 1.06–1.44; P=.008) and flat polyps than WLE (OR, 1.24; 95% CI, 1.02–1.51; 
P=.03). 
 
Conclusions: In a meta-analysis of data from individual patients in randomized controlled 
trials, we found NBI to have a higher ADR than WLE, and that this effect is greater when 
bowel preparation is optimal.  
 
KEY WORDS:  Adenoma detection Rate; colorectal cancer; serrated polyps; tumor 
 
 
Abstract Word Count : 289  
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Introduction 
Improved adenoma detection rate (ADR) at colonoscopy is associated with a decreased risk 
for the development of post colonoscopy colorectal cancer.
1-3
 Therefore, optimizing ADR has 
become a key quality indicator in the effort to make colonoscopy more effective for 
colorectal cancer prevention. Narrow band imaging (NBI) is a blue light technology that 
enhances visualization of superficial mucosal structures, especially superficial 
microcapillaries and has been clinically available since 2005.
4, 5
 This technique has been 
investigated widely at colonoscopy to detect and characterise neoplastic lesions. Whilst 
characterisation of detected lesions has been demonstrated to be more accurate with NBI 
than white light, it has been more difficult to demonstrate a benefit in primary detection of 
dysplasia.
6, 7
 As adenomas have increased vascularity and look brown with NBI against a 
blue-green normal background mucosa, it was hypothesized that this increased contrast 
might improve visualization in wide field observation. However, in five meta-analyses
8-12
 
using pooled data including up to 14 studies and 5074 patients, no statistically significant 
increase in ADR (risk or odds ratios 1.01-1.09) or polyps detected per patient was shown 
with NBI, and only one of four meta-analyses demonstrated an increase in flat adenomas (RR 
1.96, 95% CI 1.09-3.52).
11, 13
 
 
There has also been interest in the use of NBI to detect serrated polyps which are relatively 
hypovascular and look pale against the background mucosa with NBI.
14
 A 3-fold increase in 
hyperplastic polyp detection was seen in a study of NBI in sporadic patients
15
, and a 
subsequent single centre back-to-back study in serrated polyposis syndrome patients 
suggested a benefit with a polyp miss rate for NBI of 10% vs 36% for white light, P < 0.001 
16
; 
however this benefit was not replicated in a larger multi-centre parallel group study.
17
 A 
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further study in sporadic patients using the new 2
nd
 generation bright NBI also did not show 
a statistically significant increase in proximal serrated polyp detection, P = 0.085.
18
 2
nd
 
generation bright NBI systems available since 2012 differ from 1
st
 generation NBI by having a 
stronger Xenon light source and new signal processing leading to a brighter image which 
might improve detection. 
 
The issue of the importance of high-quality bowel preparation in advanced imaging with NBI 
has also been considered. Stool appears brick red with NBI and even a thin film of stool and 
mucus can significantly impair mucosal visualization. In a post hoc analysis of a parallel group 
randomized control trial (RCT) on NBI vs white light for detection in high risk patients, bowel 
preparation quality was found to be associated with polyp and adenoma detection. In 
patients with “good” bowel preparation there was a statistically significant benefit of NBI 
over white light for adenoma detection [comparison ratio 1.55 (95% CI 1.01-2.22), P = 0.04], 
whereas there was no difference between NBI and white light when preparation was 
“fair”.
19
 
 
NBI does not currently appear to increase ADR although there may be specific situations 
where NBI may be helpful, either in detecting flat adenomas, detecting serrated lesions, or 
may only work when the bowel preparation is optimal. Differences in performance of 1
st
 vs 
2
nd
 generation bright NBI are unknown. These questions are difficult to address with meta-
analysis of aggregated study level data. Accordingly, we conducted a meta-analysis of data 
from individual patients in RCTs which compared NBI with WLE for the detection of colonic 
polyps, with a primary aim to stratify for bowel preparation quality.  
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Methods 
Search strategy and study selection 
Electronic databases (MEDLINE [Ovid; 1946], EMBASE [Ovid; 1984], CENTRAL [The Cochrane 
library; 2017, Issue 7], and the Cochrane library) were searched from inception to April 2017 
using pre-defined search terms (Appendix A). After the screening of citations and abstracts 
derived from the electronic search, complete manuscripts of potentially relevant studies 
were then reviewed and the selection criteria was applied. 
 
Study eligibility criteria 
Studies were eligible if they fulfilled the following criteria: (i) RCTs of high definition white 
light and high definition NBI 1
st
 generation (EVIS LUCERA SPECTRUM or EXERA II; Olympus, 
Tokyo, Japan) or high definition NBI 2
nd
 generation bright (EVIS LUCERA ELITE or EXERA III; 
Olympus, Tokyo, Japan) for the detection of colonic polyps; (ii) bowel preparation quality 
assessed; (iii) patient level data available for analysis. Studies focussed on inflammatory 
bowel disease or patients with familial or genetic syndromes e.g. Lynch syndrome or 
Serrated Polyposis Syndrome were excluded. 
 
Risk of bias assessment 
The Cochrane Collaboration risk of bias tool 
20
 was used for assessment of risk of bias 
by two independent investigators (SK and NA). Disagreements were resolved by discussion. 
Seven domains (random sequence generation, allocation concealment, blinding of 
participants and personnel, blinding of outcome assessment, incomplete data, selective 
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reporting and other potential sources of bias) were rated as having unclear, low or high risk 
of bias in Appendix B. Publication bias was assessed via a funnel plots and Begg’s test. 
Data synthesis and statistical analysis 
Anonymised patient level data was obtained from the original investigators. The primary 
outcome measures used in the original data sets can be found in Appendix C.  Due to 
heterogeneity of the data sets, only fields consistently collected across all studies were 
extracted and pooled together in a common format. These fields were age, gender, bowel 
preparation quality, polyp number, histology and the use of white light or NBI was collected. 
Specific data regarding polyp morphology, histology and location was also heterogeneous; 
however, total polyp number and number of adenomas were consistently recorded, thus 
two groups were defined; “adenomas” and “non-adenomas”. Further polyp details were 
inconsistently available for sub-group allocation. Data was cleaned, extracted and collected 
per polyp in a common data format.  
 
Additional fields such as polyp size, segmental location, indication for colonoscopy and 
withdrawal time were not consistently collected resulting in insufficient data for these 
outcomes to be included in the primary data analysis; however we were able to dichotomize 
colonoscopy indication into screening or non-screening, and polyp location into right side of 
colon (proximal to the splenic flexure) or left side of colon including the rectum.   
 
Bowel preparation terms and classifications varied between studies.  The definitions used in 
studies are outlined in Appendix D. These heterogeneous bowel preparation scores were 
dichotomised by identifying the cleanest bowel preparation category for each study, which 
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was termed ‘best’, and grouping all other categories as ‘adequate’ bowel preparation. 
Participants that had inadequate bowel preparation were excluded.  
 
All analyses were performed at the patient level using multilevel regression methods. Two-
level models were used, with patients nested within trials. A trial level random effect was 
included for each outcome to measure the treatment difference. This allowed differences in 
outcome between white light and NBI to vary between trials, however this did not improve 
the fit for any models.   
 
 Binary outcomes were analyzed using multilevel logistic regression. Outcomes relating to 
the number of adenomas were analysed using multilevel negative binomial regression to 
allow for the strongly positively skewed distributions.  Where insufficient information on 
secondary outcomes were available, those records were included for the primary outcome 
and number of polyps detected, but censored from secondary analyses. A full list of the 
studies included in each analysis is given in Appendix C.  
 
Outcome assessment  
The primary outcome measures were i) ADR (proportion of patients with at least one 
adenoma) and ii) the ADR stratified by quality of the bowel preparation on a binary scale 
“best” vs “adequate” for white light vs NBI.  
The secondary outcome measures were i) the number of adenomas detected, ii) the number 
of adenomas against quality of the bowel preparation, and iii) the polyp detection rate (PDR; 
proportion of patients with at least one polyp) and the number of polyps detected against 
quality of bowel preparation. Pre-specified polyp based subgroup analyses were performed 
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for non-polypoid “flat” (Paris 0-II)
21
 adenomas and polyps and for non-adenomatous 
(presumed serrated) lesions including dichotomising for left side vs right side of the colon. 
Additional a priori exploratory analyses were performed according to biologically plausible 
sub-groups including age (<65 vs ≥65 years), gender, indication (screening vs non-screening), 
and generation of NBI system (1
st 
vs 2
nd
 bright generation NBI). The effect of bowel 
preparation quality and NBI system generation on non-adenomatous polyp detection and on 
flat adenoma detection was performed, as well as examining the effects of these factors in 
combination, specifically bowel preparation, generation of NBI system and colonoscopy 
indication. 
 
Results 
 
Search Results 
The full search strategy identified 1,355 studies between 1950 and April 2017 as outlined in 
the PRISMA flow diagram
22
 (Figure 1, Appendix E); however the first NBI clinical study was 
published in 2004. After the duplicates were removed, 1,326 articles did not meet the 
inclusion criteria. Thus 29 full text articles were assessed, of which 11 trials were considered 
eligible for inclusion. Trials were performed in Japan
23-25
, Italy
26, 27
, USA
18, 28, 29
 , Colombia
30
 , 
Hong Kong
31
 and the United Kingdom.
32
 Eight trials randomized patients to examination 
during withdrawal with either white light or NBI. The other three included trials randomized 
patients to tandem colonoscopy.
23, 28
 In these studies, we used the first pass dataset to 
simulate a parallel group study, and disregarded the second pass. There was little evidence 
of publication bias for ADR, with most of the studies lying within the 95% confidence interval 
of the funnel plot (Figure 2, Appendix F), Begg’s test P = 0.35. 
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Participant characteristics 
A total of 4491 participants were included. The median age of the participants was 63 ± 10 
years (± standard deviation, range 18-89) and 62% were male. A total of 6636 polyps were 
removed, of which 4920 were adenomas. 29% of participants had the ‘best’ bowel 
preparation (Table 1). 
 
Primary outcome – Adenoma Detection Rate 
For the primary outcome measure of ADR, 1011/2239 (45%) participants randomized to NBI 
had adenomas compared with 952/2251 (42%) participants randomized to WLE [unadjusted 
OR 1.14; 95% CI 1.01 to 1.29, P = 0.04] (Table 2).  Comparing the ADR in the NBI group with 
the white light group adjusted for quality of bowel preparation, no significant difference was 
observed in the ‘adequate’ bowel prep group [OR 1.07 (95% CI 0.92 to 1.24), P = 0.38], 
number needed to treat  (NNT) 55.6; however the odds of detecting at least one adenoma in 
the ‘best’ bowel preparation group was  significantly higher with NBI compared to WLE [OR 
1.30 (95% CI 1.04 to 1.62), P = 0.02], NNT 17.2. 
Secondary Outcomes 
When study-level was included as a random effect in the regression model, no difference 
was observed in model performance for the primary outcome, indicating there was no 
evidence the treatment effect varied by study. For the number of adenomas detected there 
was no significant model improvement by including a study-level random effect for 
treatment suggesting that there is no strong evidence that treatment effect varied by study.  
 
There was a non-significant trend toward more adenomas detected by NBI than by white 
light with 10% more adenomas being detected with NBI [Ratio 1.10 (95% CI 0.99 to 1.22), P = 
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0.07], but no difference in the number of adenomas detected between treatment and bowel 
preparation quality was observed (Table 3). There was a significant increase in both the 
polyp detection rate overall with NBI [OR 1.17 (1.03 to 1.32), P = 0.01]; however, when 
stratified for bowel preparation quality this was only observed in the “best” prep group [OR 
1.43 (1.14 to 1.79)], P = 0.002 (Table 2). This finding was replicated when considering polyp 
numbers both in terms of an increase in polyp numbers overall detected by NBI, and that 
this finding only retained statistical significance when bowel preparation was “best” [OR 
1.18 (95% CI 1.03 to 1.63), P = 0.02], but not when adequate (Table 3).  
 
Additional analyses considered the further polyp level secondary outcomes (Table 4); there 
were significant differences in favour of NBI in the odds of a patient having at least one non- 
adenomatous polyp [OR 1.24 (95% CI 1.06 to 1.44), P = 0.008], at least one right sided non-
adenomatous polyp [OR 1.35 (95%CI 1.05 to 1.74, P = 0.02), and at least one flat polyp [OR 
1.24.(95% CI 1.02 to1.51)  P = 0.03]. No significant difference was observed for ADR by 
colonic location or for non-polypoid adenomas. Table 5 shows how bowel preparation and 
NBI system generation affected the detection of non-adenomatous polyps, where a 
statistical trend to improved detection of non-adenomatous polyps was seen with NBI 
compared to white light when bowel preparation was either adequate or best, ORs 1.21 
(95% CI 1.00 to 1.47) and 1.28 (95% CI 0.98 to 1.67) respectively. Similarly, NBI showed a 
trend towards improved detection irrespective whether 1
st
 or 2
nd
 generation bright NBI 
systems were used ORs 1.22 (95% CI 1.00 to 1.50) and 1.24 (95% CI 0.97 to 1.58) 
respectively. Results for the secondary outcomes measured on a continuous scale are 
summarized in Table 8 (Appendix G), with confirmation of a significant difference for total 
numbers non-adenomatous polyps in favour of NBI [OR 1.26 (1.09 to 1.46), P = 0.003]. In a 
post hoc analysis for the effect of bowel preparation on the detection of flat (non-polypoid) 
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adenomas, NBI detected significantly more flat adenomas when bowel preparation was best 
[OR 1.45 (1.01 to 2.07)], P = 0.05, but not when adequate (Table 9, Appendix G) 
 
NBI performed significantly better than white light for non-screening patients than for 
screening patients both in terms of ADR [OR 1.27 (95% CI 1.09 to 1.49), P = 0.003, and in 
total numbers of adenomas detected (Table 6 and Table 9, Appendix G). Similar results were 
seen for number of polyps detected (Table 11, Appendix G). The odds of detecting at least 
one adenoma with 2
nd
 generation bright NBI vs white light was significantly higher than with 
WLE (OR 1.28 (95% CI 1.05 to 1.56), P = 0.02; however, this effect was not observed for 1
st
 
generation NBI [OR 1.06 (95% CI 0.91 to 1.24), P = 0.48] (Table 6). This effect of generation 
of NBI system was not statistically significant when number of adenomas were considered 
(Table 10, Appendix G) but was statistically significant when number of polyps were 
considered for 2
nd
 generation bright NBI vs WLE [OR 1.20 (95% CI 1.05 to 1.37), P = 0.007] 
(Table 11, Appendix G). 
 
Table 7 shows the results of the combined effects on polyp detection after stratification by 
bowel preparation, NBI system generation and colonoscopy indication. No statistically 
significant interaction was seen for adenoma detection; however there was some evidence 
of interaction for polyps detection rate for NBI generation and bowel preparation when 
colonoscopy indication was removed from the model (interaction p-value P = 0.08 and P = 
0.04 respectively). Accounting for colonoscopy indication (screening vs non-screening), no 
significant difference when preparation was adequate with 1
st
 generation NBI; however, 
both 1
st
 and 2
nd 
generation bright NBI were associated with significantly higher polyp 
detection rates in those with a “best” prep, and also if the prep was adequate using the new 
2
nd
 generation bright NBI. The largest effect was for patients with a “best” prep using 2
nd
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generation bright NBI, where the odds of detection were more than 60% higher with NBI 
than for WLE [OR 1.64 (95% CI 0.25 to 2.16)], P < 0.001. 
 
Discussion 
This is the first meta-analysis that utilized individual patient level data from RCTs comparing 
1
st
 and 2
nd
 generation high definition NBI vs high definition WLE, that also defined bowel 
preparation quality, with ADR as an outcome. Our main finding indicated a statistically 
significant 14% increase in the odds of detecting at least one adenoma for NBI compared to 
WLE when the data was combined from 4491 patients across six countries, but not in the 
total number of adenomas detected. Furthermore, this improvement in ADR with NBI only 
maintained statistical significance when bowel preparation was stratified to “best” quality. 
This effect of bowel preparation remained consistent when the analysis was conducted for 
polyp detection rate and for when the numbers of polyps were considered (Tables 2 and 3), 
and when we controlled for generation of NBI system and colonoscopy indication (Table 7) 
Previous studies have suggested that bowel preparation scores correlate with polyp 
detection, both in the use of WLE alone
33
 and NBI over white light.
19
 In a previous study we 
found that when bowel preparation was good, NBI performed significantly better than WLE 
for total polyp number and adenoma detection
19
, but there was no difference between the 
NBI and WLE group when the bowel preparation was only fair. In contrast, the individual 
findings of Sabbagh
30
 and Kaltenbach
28
 did not demonstrate this effect. In the current meta-
analysis of data from individual patients in RCTs, when the preparation was “best”, NBI was 
associated with a 5.8% increase in the ADR, with a NNT of 17.2. This is consistent with the 
idea that for advanced endoscopic imaging optimal bowel preparation is required, and that 
even slightly sub-optimal bowel preparation may negate the benefits. When the preparation 
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was only adequate, the ADR only increased by an absolute 1.8%, and NNT rises to 55.6; 
however, when we analysed for non-adenomatous polyps stratified for bowel preparation, 
NBI improved detection for both adequate and best preparation (Table 5). Studies in 
colonoscopy screening programmes or in community based cohorts have indicated that for 
serrated polyps optimal bowel preparation did not lead to improved serrated lesion 
detection
34, 35
. A hypothesis to explain this may be that adherent stool on serrated lesions 
may help direct the endoscopist investigate the mucosal surface more carefully to detect 
these subtle lesions, which might be washed off by “best” bowel preparation. 
 
Unlike prior meta-analyses, we were able to include three 2
nd
 generation bright NBI studies 
in our study with patient level data. When we stratified for this modality, we found that use 
of NBI led to significantly more patients with least one adenoma detected with 2
nd
 
generation bright NBI, but not with 1
st
 generation NBI, with the odds of detecting at least 
one patient with an adenoma being 28% higher with 2
nd
 generation bright NBI vs 6% with 1
st
 
generation NBI (Table 6). A similar result was seen for number of polyps detected overall. 
This finding is consistent with another next generation bright blue light advanced imaging 
system, Blue-laser imaging (BLI; LASEREO; Fujifilm Co, Tokyo, Japan), which superseded the 
darker Flexible spectral Imaging Color Enhancement (FICE; Fujifilm Co, Tokyo, Japan) system. 
FICE did not improved ADR in meta-analysis
12
, whereas BLI appears to increase mean 
adenomas detected and reduces adenoma miss rates in early studies
36, 37
  
 
The role of NBI in the detection of non-adenomatous polyps has been unclear. We found 
that NBI is beneficial for the detection of non-adenomatous polyps, both numbers of 
patients with at least one non-adenomatous polyp detected and in numbers of non-
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adenomatous polyps (Table 4).  This increase in non-adenomatous polyp detection was also 
seen in the study by Paggi and colleagues
27
, and was of borderline statistical significance in 
the study by Rex and colleagues
18
. From this patient level data, it is unclear what proportion 
of the non-adenomatous polyps were sessile serrated polyps. However, when the analysis 
was limited to non-adenomatous polyps in the proximal colon which are more likely to be 
sessile serrated polyps, the results remained statistically significant for patients with at least 
one non-adenomatous polyp, although this should be interpreted with caution due to the 
smaller sample size. We also investigated the role of NBI system generation in the detection 
of non-adenomatous polyps, where there was a statistical trend to improved non-
adenomatous polyp detection with either 1
st
 or 2
nd
 generation bright NBI, in contrast to the 
data for adenoma detection where only 2
nd
 generation bright NBI significantly improved 
detection (Table 5 and 6). Increasing evidence highlights the clinical importance of sessile 
serrated polyps and their role in interval cancers.
38, 39
 This is of concern due to the difficulty 
in endoscopic detection, both due to their flat nature but also that sessile serrated polyps 
with dysplasia or malignancy are small, with a median polyp size of 9mm, and that in 83% 
the neoplastic component is flat.
40
 
 
We also considered whether non-polypoid “flat” (Paris 0-II) adenomas might be better 
detected with NBI, with one study level meta-analysis suggesting a benefit, with a relative 
Risk, 1.96; 95% CI, 1.09–3.52
11
, though three other study level meta-analyses were negative
8-
10
. Our study confirms that the odds of patients having at least one non-polypoid “flat” polyp 
was increased by 24% using NBI, but we did not demonstrate a significant effect for having 
at least one non-polypoid adenoma. This may be driven by the increase in non-adenomatous 
polyps with NBI where serrated polyps are much more likely to be non-polypoid. However, 
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we did find an increase in non-polypoid adenoma detection when bowel preparation was 
“best” (Table 9, Appendix G) which is again consistent with the concept that bowel 
preparation needs to be optimised for adenoma detection with NBI. 
 
There are number of possibilities why this individual patient level data meta-analysis found 
significant differences between NBI and WLE, in contrast to previous meta-analyses. First, 
the current dataset represents the largest to date for sporadic lesions both in terms of 
patient numbers, polyp numbers and number of studies, leading to greater statistical power 
to detect smaller differences. Second, our unique ability to look at patient level factors 
including bowel preparation, polyp pathology, morphology and position in the colon, sex, 
colonoscopy indication, age and generation of NBI has allowed further insights to be 
obtained not possible from study level data. Third, we included data from 2
nd
 generation 
bright NBI studies which seemed to perform better than 1
st
 generation NBI. Fourth, we were 
able to investigate the effects of bowel preparation and NBI system generation in 
combination on polyp detection. 
 
Several limitations from this study should be acknowledged. First, the data sets were 
somewhat heterogeneous and are not precisely aligned in descriptors used and did not all 
report all outcomes in a consistent way. Nevertheless, the level of detail available 
substantially exceeds other meta-analyses and the heterogeneity in outcome reporting is a 
well-recognized problem in clinical trials. Secondly, since we focused on the effect of bowel 
preparation on NBI performance as our primary outcome, we may have excluded studies 
reporting on our secondary outcomes, although, our patient level sample sets included at 
least three studies.  
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Third, we had limited histological information on non-adenomatous polyps or their size, 
which may be relevant as small non-adenomatous polyps may not be clinically important. 
Many studies were started prior to the appreciation of the importance of sessile serrated 
polyps, and may not have had the histopathological expertise to report these. Therefore, not 
all non-adenomatous polyps will be of the serrated class, and of the serrated class polyps not 
all will be sessile serrated polyps. However, when the results are sub-analysed to only 
examine the non-adenomatous polyps in the right colon to avoid contamination by multiple 
rectal hyperplastic polyps, a significant difference persisted. Fourth, we did not include 
patients with ulcerative colitis or those at high genetic risk e.g. Lynch syndrome or serrated 
polyposis syndrome. Fifth, the size of the clinical benefit seen is limited, for example a 2.9% 
absolute benefit in ADR in all studies of NBI vs WLE, though larger absolute benefits were 
seen with “best” bowel preparation and 2
nd
 generation bright NBI, 5.8% and 6.0% 
respectively. The greatest benefit was seen when both prep was best and 2
nd
 generation 
bright NBI was used with an associated 60% relative increase in ADR. This should be seen in 
the context of expert performance with high definition WLE with a baseline ADR of more 
than 40%. Sixth, not all analyses that showed significance in a binary analysis e.g. ADR, also 
showed significance in when analysed as a continuous variable e.g. adenoma number. This 
may reflect the “one and done” phenomenon, where once one adenoma is detected the 
endoscopist is less motivated to keep searching for further lesions
41
 . Finally, the number of 
sub-group analyses is high risking a false positive result by chance, and therefore results of 
secondary analyses should be considered exploratory or hypothesis generating. 
 
In conclusion, in this large meta-analysis of data from 4491 individual patients in randomized 
controlled trials, we found NBI significantly improved ADR compared to high definition WLE 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
and was consistent with our hypothesis that this effect is greater when bowel preparation is 
optimal. Secondary subgroup analysis suggests that 2
nd
 generation bright NBI improved ADR, 
and that NBI was more effective for detecting non-adenomatous polyps. 
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Tables 
Table 1: Study demographics 
Study # 
of 
patients 
Age 
($)
 
 
Male 
Gender 
Screening 
Indication 
Total # of 
polyps 
Total # of 
adenomas 
Best prep 
East (UK) 214 64 ± 9 60% 28% 606 422 33% 
Horimatsu (Japan) 431 64 ± 12 67% 0% 760 643 28% 
Ikematsu (Japan) 782 63 ± 10 70% 6% 772 583 32% 
Kaltenbach (USA) 266 64 ± 10 97% 52% 399 - 43% 
Leung (Hong Kong) 360 62 ± 11 48% 10% 395 300 9% 
Paggi (Italy) 210 60 ± 5 55% - 485 398 50% 
Rastogi (USA) 439 61 ± 9 64% 64% 757 529 8% 
Rex (USA) 799 61 ± 8 43% 50% 1407 1023 48% 
Sabbagh (Colombia) 478 58 ± 13 37% 72% 
(*)
 196 - 4% 
Saracco (Italy) 269 71 ± 3 57% 100% 357 234 22% 
Inoue (Japan) 243 62 ± 12 62% 0% 202 158 60% 
Total 4491 63 ± 10 62% 33% 6636  4290 
(+)
 29% 
 
($) Figures are mean ± standard deviation 
(*) Based on data from 86/472 patients only 
(+) Based on data from 9/11 studies only 
 
Table 2: Analysis results for adenoma detection rate and polyp detection rate stratified by bowel 
preparation quality 
Bowel 
preparation 
N. 
studies 
WLE 
% (n/N) 
NBI 
% (n/N) 
Odds Ratio 
(*)
 
 (95% CI) 
P-value 
Adenomas      
All 11 42.3% (952/2251) 45.2% 
(1011/2239) 
1.14 (1.01, 1.29) 0.04 
Adequate 11 41.4% (638/1543) 43.2% (702/1625) 1.07 (0.92, 1.24) 0.38 
Best 11 44.4%  
(314/707) 
50.2%  
(307/612) 
1.30 (1.04, 1.62) 0.02 
Polyps      
All 11 53.4% 
(1203/2251) 
56.9% 
(1274/2240) 
1.17 (1.03, 1.32) 0.01 
Adequate 11 52.6% (812/1543) 54.4% (883/1622) 1.07 (0.92, 1.24) 0.37 
Best 11 55.2%  
(391/708) 
63.1%  
(388/615) 
1.43 (1.14, 1.79) 0.002 
 
(*) Calculated as odds of adenoma detection in NBI group relative to odds in WLE group 
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Table 3: Analysis results for number of adenomas and polyps stratified by bowel preparation quality 
Bowel N.  WLE NBI Ratio 
(*)
 P- 
Preparation studies N Mean (SD) N Mean (SD) (95% CI) value 
Adenomas        
All 9 1876 1.09 (1.82) 1870 1.20 (1.87) 1.10 (0.99, 1.22) 0.07 
Adequate 9 1233 1.10 (1.85) 1321 1.20 (1.90) 1.08 (0.96, 1.22) 0.21 
Best 9 642 1.08 (1.76) 547 1.19 (1.82) 1.13 (0.94, 1.35) 0.18 
Polyps        
All 11 2252 1.33 (1.96) 2239 1.49 (2.12) 1.12 (1.03, 1.21) 0.006 
Adequate 11 1543 1.29 (1.95) 1622 1.43 (2.10) 1.08 (0.98, 1.19) 0.10 
Best 11 708 1.43 (2.00) 615 1.64 (2.17) 1.18 (1.03, 1.63) 0.02 
 
(*) Calculated as number of adenomas in NBI group relative to number in WLE group 
 
Table 4:  Secondary outcomes for detection rates by polyp pathology, morphology or location sub-
groups 
 
Outcome N. 
studies 
WLE 
% (n/N) 
NBI 
% (n/N) 
Odds Ratio 
(*)
 
 (95% CI) 
P-value 
Non-adenomas 9 20.7% (388/1876) 24.2% (453/1870) 1.24 (1.06, 1.44) 0.008 
Non-adenomas 
(+)
 6 9.7% (123/1263) 12.7% (160/1260) 1.35 (1.05, 1.74) 0.02 
Non-polypoid ad. 5 17.7% (199/1124) 18.9% (213/1130) 1.10 (0.87, 1.37) 0.43 
Adenoma 
(+)
 6 32.7% (413/1262) 35.2% (444/1261) 1.12 (0.95, 1.32) 0.19 
Adenoma 
(++)
 6 15.9% (200/1262) 17.9% (226/1261) 1.22 (0.97, 1.53) 0.09 
Flat polyps 6 21.2% (267/1260) 24.5% (309/1260) 1.24 (1.02, 1.51) 0.03 
 
(*) Calculated as odds of detection in NBI group relative to odds in WLE group 
(+) Right side colon only 
(++) Left side colon only 
 
 
Table 5: Analysis results for non-adenomatous polyp detection rate stratified by bowel preparation 
quality and NBI system generation 
 
Subgroup N. 
studies 
WLE 
% (n/N) 
NBI 
% (n/N) 
Odds Ratio 
(*)
 
 (95% CI) 
P-
value 
      
Adequate prep 9 19.6% (242/1223) 22.6% (298/1318) 1.21 (1.00, 1.47) 0.05 
Best prep 9 22.7% (146/643) 27.7% (152/549) 1.28 (0.98, 1.67) 0.08 
      
1
st
 Generation 
NBI 
6 21.9% (236/1078) 25.3% (273/1078) 1.22 (1.00, 1.50) 0.05 
2
nd
 Generation 
bright NBI 
3 19.2% (153/799) 22.6% (179/791) 1.24 (0.97, 1.58) 0.09 
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(*) Calculated as odds of non-adenoma detection in NBI group relative to odds in WLE group 
 
 
 
Table 6: Subgroup analysis of adenoma detection rate according to patient characteristics and NBI 
system generation 
 
Subgroup N. 
studies 
WLE 
% (n/N) 
NBI 
% (n/N) 
Odds Ratio 
(*)
 
 (95% CI) 
P-value 
Age      
<65 11 37.5% (463/1234) 40.1% (516/1288) 1.14 (0.96, 1.34) 0.14 
≥ 65 11 48.1% (489/1017) 52.1% (495/951) 1.17 (0.97, 1.40) 0.10 
Gender      
Female 11 33.1% (311/940) 35.7% (334/936) 1.13 (0.93, 1.38) 0.21 
Male 11 48.9% (641/1311) 52.0% (677/1303) 1.15 (0.98, 1.35) 0.09 
Indication      
Screening 8 41.1% (259/631) 39.9% (264/661) 0.99 (0.79, 1.25) 0.94 
Non-scr. 9 45.8% (601/1311) 51.6% (663/1284) 1.27 (1.09, 1.49) 0.003 
NBI system      
1
st
 Generation 
NBI 
8 39.9% (579/1452) 41.0% (594/1448) 1.06 (0.91, 1.24) 0.48 
2
nd
 Generation 
bright NBI 
3 46.7% (373/799) 52.7% (417/791) 1.28 (1.05, 1.56) 0.02 
 
 
 
Table 7: Analysis for combined colonoscopy indication, bowel preparation and NBI results for polyp 
detection rate 
 
Colonoscopy 
Indication adjustment 
Subgroup Odds Ratio 
(*)
 (95% CI) Modality P-value 
    
Yes Adequate prep + 1
st
 
generation NBI  
1.07 (0.88, 1.29) 0.50 
 Adequate prep + 2
nd
 
generation NBI 
1.28 (1.02, 1.60) 0.03 
 Best prep, + 1
st
 generation 
NBI 
1.36 (1.04, 1.76) 0.02 
 Best prep + 2
nd
 generation 
NBI 
1.62 (1.22, 2.14) 0.001 
    
No Adequate prep + 1
st
 
generation NBI  
0.99 (0.83, 1.17) 0.88 
 Adequate prep + 2
nd
 
generation NBI 
1.24 (0.99, 1.55) 0.06 
 Best prep, + 1
st
 generation 
NBI 
1.31 (1.02, 1.68) 0.03 
 Best prep + 2
nd
 generation 1.64 (0.25, 2.16) <0.001 
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NBI 
    
(*) Calculated as odds of detection in NBI group relative to odds in WLE group 
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Supplementary material  
Appendix A:  Search strategy 
MEDLINE search strategy 1950 to 1.4.2017 
 
1 Adenoma/ 
2 exp Adenomatous Polyps/ 
3 exp Intestinal Polyps/ 
4 (adenoma* or polyp?).ti,ab. 
5 ((colon* or colorectal) adj3 polyp*).ti,ab. 
6 exp Colorectal Neoplasms/ 
7 1 or 2 or 3 or 4 or 5 or 6 
8 endoscopy/ or exp endoscopy, digestive system/ 
9 (endoscop* or colonoscop*).ti,ab. 
10 8 or 9 
11 (narrow band* or narrowed band or narrow spectrum or narrowed spectrum).ti,ab. 
12 10 and 11 
13 ((narrow band* or narrowed band or narrow spectrum or narrowed spectrum) adj3 imaging).ti,ab. 
14 (nbi adj3 (endoscop* or colonoscop*)).ti,ab. 
15 nbi.ti. 
16 electronic chromoendoscop*.ti,ab. 
17 12 or 13 or 14 or 15 or 16 
18 7 and 17 
19 randomized controlled trial.pt. 
20 controlled clinical trial.pt. 
21 randomized.ab. 
22 placebo.ab. 
23 drug therapy.fs. 
24 randomly.ab. 
25 trial.ab. 
26 groups.ab. 
27 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 
28 exp animals/ not humans.sh. 
29 27 not 28 
30 18 and 29 
31 18 not 29 
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 2 
EMBASE search strategy 1950 to 1.4.2017 
 
1 Adenoma/ 
2 *polyp/ or adenomatous polyp/ or exp intestine polyp/ 
3 (adenoma* or polyp?).ti,ab. 
4 ((colon* or colorectal) adj3 polyp*).ti,ab. 
5 exp *colon tumor/ or exp *rectum tumor/ 
6 1 or 2 or 3 or 4 or 5 
7 exp digestive tract endoscopy/ or endoscopy/ 
8 (endoscop* or colonoscop*).ti,ab. 
9 7 or 8 
10 (narrow band* or narrowed band or narrow spectrum or narrowed spectrum).ti,ab. 
11 9 and 10 
12 narrow band imaging/ 
13 ((narrow band* or narrowed band or narrow spectrum or narrowed spectrum) adj3 imaging).ti,ab. 
14 (nbi adj3 (endoscop* or colonoscop*)).ti,ab. 
15 nbi.ti. 
16 electronic chromoendoscop*.ti,ab. 
17 11 or 12 or 13 or 14 or 15 or 16 
18 6 and 17 
19 randomized controlled trial/ 
20 single blind procedure/ or double blind procedure/ 
21 crossover procedure/ 
22 random*.tw. 
23 ((singl* or doubl*) adj (blind* or mask*)).tw. 
24 (crossover or cross over or factorial* or latin square).tw. 
25 (assign* or allocat* or volunteer*).tw. 
26 19 or 20 or 21 or 22 or 23 or 24 or 25 
27 18 and 26 
28 18 not 26 
 
Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library), 2017 
 
#1 MeSH descriptor: [Adenoma] this term only 
#2 MeSH descriptor: [Adenomatous Polyps] explode all trees 
#3 MeSH descriptor: [Intestinal Polyps] explode all trees 
#4 (adenoma* or polyp?):ti,ab,kw  (Word variations have been searched) 
#5 MeSH descriptor: [Colorectal Neoplasms] explode all trees 
#6 #1 or #2 or #3 or #4 or #5  
#7 MeSH descriptor: [Endoscopy] this term only 
#8 MeSH descriptor: [Endoscopy, Digestive System] explode all trees 
#9 endoscop* or colonoscop*:ti,ab,kw  (Word variations have been searched) 
#10 #7 or #8 or #9  
#11 narrow band* or narrowed band or narrow spectrum or narrowed spectrum:ti,ab,kw  (Word variations have been 
searched) 
#12 #11 and #10  
#13 ((narrow band* or narrowed band or narrow spectrum or narrowed spectrum) near imaging):ti,ab,kw  (Word 
variations have been searched) 
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 3 
#14 (nbi near (endoscop* or colonoscop*)):ti,ab,kw  (Word variations have been searched) 
#15 nbi:ti  (Word variations have been searched) 
#16 electronic chromoendoscop*:ti,ab,kw  (Word variations have been searched) 
#17 #12 or #13 or #14 or #15  
#18 #6 and #17  
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 4 
Appendix B:  Risk of bias assessment 
 
Cochrane Criteria East Horimatsu Ikematsu Inoue Kaltenbach Leung Paggi Rastogi Rex Sabbagh Saracco 
Random sequence 
generation 
Low Low Low Unclear Unclear Low Low Low Low Low Low 
Allocation concealment Low Unclear Low Low Low Low Low Low  Low Low 
Blinding of participants 
and personnel 
High High High High Unclear High High High High High High 
Blinding of outcome 
assessment 
Low Low Low Low Low Low Low Low Low Low Low 
Incomplete outcome 
data 
Low Low Low Unclear Low Low Low Unclear Low Low Low 
Selective reporting Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear 
Other bias Low Low Low Low Low Low Low Low Low Low Low 
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Appendix C:  Summary of studies included in each analysis 
 
Outcome Amit East Horimatsu Ikematsu Kaltenbach Leung Paggi Rex Sabbagh Saracco Takuya 
            
Adenoma – Yes/no            
Adenoma – Number             
            
Polyps – Yes/no             
Polyps – Number            
            
Non-adenomas – Yes/no            
Non-adenomas – Number            
            
Non-aden. right c. – Yes/no            
Non-aden. right c. – 
Number 
           
            
Non-polypoid aden. – Y/N            
Non-polypoid aden. – 
Number 
           
            
Adenomas right c. – Y/N            
Adenomas right c. – 
Number 
           
            
Adenomas left c. – Yes/no            
Adenomas left c. – Number            
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Appendix D:  Definitions of bowel preparation scores in original articles 
Study  Excellent/ Optimal Good Adequate Sub-
Optimal 
Fair Poor Inadequate 
East  No more than liquid 
residue that could be 
aspirated to achieve 
near 100% 
visualization 
> 90% 
visualization 
   < 90% 
visualization - 
Excluded 
 
Horimatsu 100% mucosal 
visualization following 
suction of fluid 
residue  
90% mucosal 
visualization  
  <90% mucosal 
visualization  
Large amounts of 
solid fecal matter  
- Excluded 
 
 
Ikematsu Approximately 100% 
mucosal visualization 
following suction of 
fluid residue 
Approximately 90% 
mucosal visualization 
  Less than 90% 
mucosal 
visualization 
Large amounts of 
solid fecal matter 
were found - 
Excluded 
 
Inoue  Near 100% mucosal 
visualization after 
aspiration of liquid 
residue 
  Greater than 90% 
mucosal 
visualization 
Less than 90% 
mucosal 
visualization - 
excluded 
 
Kaltenbach Small volume of clear 
liquid or greater than 
95% of surface seen 
Large volume of 
clear liquid covering 
5% to 25% of the 
surface but greater 
than 90% of surface 
seen 
  Some semi-solid 
stool that could be 
suctioned or washed 
away but greater 
than 90% of surface 
seen. 
Semi-solid stool 
that could not be 
suctioned or 
washed away and 
less than 90% of 
surface seen 
Repreparation 
needed - Excluded 
Leung ~100% of colonic 
mucosal visualization  
~95% mucosal 
visualization  
  > 90% mucosal 
visualization  
 
< 90% mucosal 
visualization  
 
 
Paggi Minimal amount of 
liquid stools 
Mainly liquid stools, 
frequent aspiration 
needed, no 
limitation of the 
  Liquid and semisolid 
stools, frequent 
aspiration and 
washings needed; 
 More than 10% of 
mucosa not 
visualized, 
presence of solid 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 7 
examination small lesions might 
be missed 
or semisolid stools; 
aspiration not 
possible, repetition 
of the examination 
required - Excluded 
Sabbagh Excellent Good   Fair Poor - Excluded Inadequate - 
Excluded 
Saracco Minimal amount of 
liquid stools 
  Mainly 
liquid 
stools, no 
limitation 
of the 
examinati
on 
Liquid and semisolid 
stools - Excluded 
 Impossible to 
perform a reliable 
examination, 
repetition of 
procedure 
required - Excluded 
Rastogi > 90% of mucosa 
seen, mostly liquid 
colonic contents, 
minimal suctioning 
needed for adequate 
visualization 
> 90% of mucosa 
seen, mostly liquid 
colonic contents, 
significant suctioning 
needed for adequate 
visualization 
  > 90% of mucosa 
seen, mixture of 
liquid and semisolid 
colonic contents, 
could be suctioned 
and/or washed 
 < 90% of mucosa 
seen, mixture of 
semisolid and solid 
colonic contents, 
which could not be 
suctioned or 
washed - Excluded 
Rex Excellent Good   Fair  Too difficult to 
correct with 
intraprocedural 
washing 
procedures  
 - Not randomised 
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Appendix E: Figure 1. PRISMA flow chart of study selection 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 9 
 
 
Appendix F: Figure 2. Funnel plot to assess publication bias for adenoma detection rate 
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Appendix G: Additional data tables 
 
Table 8:  Secondary outcomes for detection numbers by polyp pathology, morphology or location sub-groups 
 
Outcome N. 
studies 
WLE 
Mean (SD) 
NBI 
Mean (SD) 
Ratio 
(*)
 
 (95% CI) 
P-value 
Non-adenomas 9 0.33 (0.84) 0.41 (0.95) 1.26 (1.09, 1.46) 0.003 
Non-adenomas 
(+)
 6 0.16 (0.71) 0.18 (0.56) 1.15 (0.88, 1.50) 0.30 
Non-polypoid ad 5 0.32 (0.91) 0.33 (0.89) 1.00 (0.80, 1.24) 0.97 
Adenoma 
(+)
 6 0.67 (1.45) 0.76 (1.48) 1.13 (0.97, 1.31) 0.11 
Adenoma 
(++)
 6 0.24 (0.65) 0.27 (0.70) 1.17 (0.97, 1.43) 0.11 
Flat polyps 6 0.40 (1.03) 0.46 (1.06) 1.09 (0.91, 1.31) 0.35 
      
 
(*) Calculated as number in NBI group relative to number in WLE group 
(+) Right side colon only 
 
Table 9. Detection of non-polypoid “flat” adenomas stratified by bowel preparation quality and NBI generation  
 
Subgroup N. 
studies 
WLE 
% (n/N) 
NBI 
% (n/N) 
Odds Ratio 
(*)
 
(95% CI) 
P-value 
      
Adequate prep 6 19.7% (174/883) 22.5% (213/945) 1.17 (0.92, 1.48) 0.21 
Best prep 6 24.7% (93/377) 30.5% (96/315) 1.45 (1.01, 2.07) 0.05 
      
1
st 
Generation 
NBI 
4 19.8% (171/862) 23.4% (203/867) 1.25 (0.99, 1.59) 0.06 
2nd Generation 
“bright” NBI 
2 24.1% (96/398) 22.6% (106/393) 1.20 (0.85, 1.70) 0.29 
      
(*) Calculated as number of adenomas in NBI group relative to number in WLE group 
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Table 10: Subgroup analysis of adenoma numbers according to patient characteristics and NBI system generation 
 
Subgroup N. WLE NBI Ratio 
(*)
 P- 
 studies N Mean (SD) N Mean (SD) (95% CI) value 
        
Age <65 9 1003 0.96 (1.70) 1028 1.04 (1.73) 1.07 (0.92, 1.24) 0.37 
Age 65+ 9 873 1.25 (1.94) 842 1.39 (2.02) 1.13 (0.99, 1.30) 0.07 
        
Female 9 791 0.74 (1.32) 777 0.92 (1.69) 1.20 (1.01, 1.43) 0.04 
Male 9 1085 1.35 (2.07) 1093 1.40 (1.97) 1.05 (0.93, 1.19) 0.40 
        
Screening 6 532 0.99 (1.94) 561 1.02 (1.78) 1.05 (0.85, 1.30) 0.64 
Non-scr. 7 1237 1.07 (1.73) 1205 1.21 (1.85) 1.14 (1.01, 1.28) 0.04 
        
1
st
 Generation 
NBI 
6 1077 1.04 (1.78) 1079 1.12 (1.84) 1.08 (0.94, 1.23) 0.28 
2nd Generation 
“bright” NBI 
3 799 1.17 (1.88) 791 1.31 (1.92) 1.13 (0.97, 1.31) 0.12 
        
(*) Calculated as number of adenomas in NBI group relative to number in WLE group 
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Table 11: Subgroup analysis of polyp numbers according to patient characteristics and NBI system generation 
 
Subgroup N. WLE NBI Ratio 
(*)
 P- 
 studies N Mean (SD) N Mean (SD) (95% CI) value 
        
Age <65 11 1234 1.16 (1.82) 1287 1.29 (1.94) 1.11 (0.99, 1.24) 0.08 
Age 65+ 11 1018 1.54 (2.10) 952 1.77 (2.31) 1.14 (1.02, 1.28) 0.02 
        
Female 11 940 0.92 (1.50) 937 1.14 (1.89) 1.20 (1.04, 1.38) 0.01 
Male 11 1312 1.63 (2.19) 1302 1.74 (2.24) 1.09 (0.99, 1.19) 0.09 
        
Screening 8 631 1.33 (2.10) 661 1.39 (1.95) 1.06 (0.91, 1.24) 0.47 
Non-scr. 9 1311 1.39 (1.94) 1285 1.65 (2.24) 1.19 (1.08, 1.31) 0.001 
        
1
st
 Generation 
NBI 
8 1453 1.25 (1.88) 1448 1.35 (2.01) 1.07 (0.97, 1.18) 0.20 
2nd Generation 
“bright” NBI 
3 799 1.47 (2.09) 791 1.75 (2.29) 1.20 (1.05, 1.37) 0.007 
        
(*) Calculated as number of adenomas in NBI group relative to number in WLE group 
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4491 individual 
patient datasets
11 international centers
Odds ratio 
(95% CI)
1.14 
(1.01–1.29)
1.07 
(0.92–1.24)
1.30 
(1.04–1.62)
Individual patient level data meta-analysis for high definition White Light Endoscopy 
(WLE) vs Narrow Band Imaging (NBI) stratified by bowel preparation
P =.04 P =.38 P =.02
